Dr Ellen L. Edens joins Ethics Talk to discuss her article, coauthored with Drs Gabriela Garcia Vassallo and Robert Heimer: "How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?”
Dr Brady J. Heward joins Ethics Talk to discuss his article, coauthored with Drs Amy M. Yule and Peter R. Jackson: “How Should Harm Reduction Strategies Differ for Adolescents and Adults?”
An ethical case describes the use of a pharmacy's database to market directly to their patients without either patient consent or disclosure of the marketing intent of the materials they received.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
A case that explores the impact of financial incentives from insurance companies on the patient-physician relationship and whether or not they should be disclosed to a patient.
Dr Oluwole Jegede joins Ethics Talk to discuss his article, coauthored with Drs Julio C. Nunes, Terence Tumenta, Carmen Black, and Joao P. De Aquino: “What Would Equitable Harm Reduction Look Like?”
Physicians need to understand when it may be appropriate to let patients get involved in medical decision-making and when it may be necessary to provide their personal medical judgment.